EP0316017B1 - 2',3'-Dideoxy-2'-fluoronucleosides - Google Patents
2',3'-Dideoxy-2'-fluoronucleosides Download PDFInfo
- Publication number
- EP0316017B1 EP0316017B1 EP88118870A EP88118870A EP0316017B1 EP 0316017 B1 EP0316017 B1 EP 0316017B1 EP 88118870 A EP88118870 A EP 88118870A EP 88118870 A EP88118870 A EP 88118870A EP 0316017 B1 EP0316017 B1 EP 0316017B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- hydroxy
- purine
- pyrimidine
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 BC1OC(CO*)CC1 Chemical compound BC1OC(CO*)CC1 0.000 description 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- This invention relates to 2′,3′-dideoxy-2′-fluoronucleosides and 2′,3′-dideoxy-2′,3-didehydro-2′-fluoronucleosides, their preparation, and their use in HIV infection.
- compound B [6-amino-( ⁇ ′ D -2′,3′-dideoxy-2′-fluororibofuranosyl)-9- H -purine; 2′-F-ddA] and compound C [6-amino-9-( ⁇ - D -2′,3′-dideoxy-2′-fluoroarabinofuranosyl)- H -purine; 2′-F-ara-ddA].
- Compound B was obtained from 3′-deoxy-ara-A (compound D) in four steps which involved protection of the 5′-hydroxyl group with dimethoxytrityl chloride, activation of the 2′-hydroxyl group via formation of the corresponding triflate, inversion of configuration at the 2′-position by an SN2 displacement using tetra- n -butylammonium fluoride, and removal of the dimethoxytrityl protective group using dichloracetic acid.
- Compound C was prepared by condensing 6-chloropurine with 3- O -acetyl-5- O -benzyl-2-deoxy-2-fluoro-D-arabinofuranosyl bromide, separating the expected four isomers and characterizing the correct 6-chloro isomer, and subjecting the correct isomer to ammonolysis with concentrated methanolic ammonia to give Compound E, 6-amino-9-( ⁇ - D -2′deoxy-2′-fluoroarabinofuranosyl)-9 H -purine (2′F-ara-dA; compound E).
- U.S. Serial No. 028817 corresponding to EP-A-285 884, discloses a process for producing 2',3'-dideoxynucleosides represented by the formula.
- Brundidge et al ., U.s. Patent 4,625,020 discloses a process for producing 1-halo-2-deoxy-2-fluoroarabinofuranoside derivatives (Compound of Formula F), bearing protective ester groups, from 1,3,5-tri-O-acyl-ribofuranose.
- the 1-halo derivatives are intermediates in the synthesis of therapeutically active nucleosidic compounds (compound of Formula G).
- Lopez et al ., EP Patent App. Publication No. 0,010,205 discloses 5-substituted 1-(2′-deoxy-2′-substituted-beta-D-arabinofuranosyl)pyrimidine nucleosides wherein the 2′-substituent, X, is halogen, alkylsulfonyl or arylsulfonyl (compound of Formula H).
- This invention comprises novel 2',3'-dideoxy-2'-fluoronucleosides and 2'-3'-dideoxy-2',3'--didehydro-2'-fluoronucleosides and processes for their preparation.
- the compounds exhibit therapeutically useful antiviral effects and are useful as anti-human immunodeficiency virus (anti-HIV) infection agents.
- anti-HIV anti-human immunodeficiency virus
- this invention is a compound having the formula wherein:
- this invention is a compound having the formula wherein:
- this invention is a process for producing a compound according to Formula I comprising the steps of:
- this invention is a process for producing a compound according to Formula II comprising the steps of:
- this invention is a process for producing a compound according to Formula I comprising the steps of:
- this invention is a process for producing a compound according to Formula-I wherein B is derived from a member of the group of bases consisting of uracil, thymine, cytosine, and guanine and wherein R is a member of said group of above-mentioned substituents comprising the steps of:
- this invention is a pharmaceutical composition
- a pharmaceutical composition comprising an antiviral effective amount of the compound according to one of Formulas I and II and a pharmaceutically acceptable carrier.
- this invention is a method of treating an animal to eliminate or reduce the infection with the human immunodeficiency virus (HIV) by administering to said animal an anti-human immunodeficiency virus effective amount of a compound according to one of Formulas I and II.
- HAV human immunodeficiency virus
- the base component B is derived from a member selected from the group of bases consisting of purine (except adenine), aza-purine, deaza-purine, pyrimidine, aza-pyrimidine, deaza-pyrimidine, and triazole ring bases.
- the base is selected from purine and pyrimidine bases. More preferably, the base is a pyrimidine base including one of the group of uracil, thymine and cytosine.
- Suitable purine bases include those purine bases represented by the structural formula wherein R1 and R2 may be the same or different and are selected from hydrogen, hydroxy, halo (F, Cl, Br), amino, monoalkylamino, dialkylamino, alkoxy and cyano groups wherein the alkyl moiety is selected from C1-C3 alkyl groups, provided that R2 is not H and R1 is not NH2.
- Suitable pyrimidine bases include those pyrimidine bases represented by the structural formula wherein R3 is selected from hydroxy, amino and sulfhydryl groups; R 4 is hydrogen; R5 is selected from hydroxy and amino groups; and R6 is selected from hydrogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 haloalkenyl having from 1 to 5 halo groups as defined herein, C2-C3 alkynyl, alkoxy wherein the alkyl moiety has 1-3 carbon atoms, cyano and halo (F, Cl, Br and I).
- B When derived from purine bases, representative of B are the following: 2-aminopurin-9-yl 2,6-diaminopurin-9-yl 2-amino-6-hydroxypurin-9-yl (guanin-9-yl) 6-hydroxypurin-9-yl
- the B component may be 2-halopurin-9-yl, 6-halopurin-9-yl, or 2,6-dihalopurin-9-yl, in which event the base component need not be activated, for example, completely silylated, in order to undergo the condensation or coupling reaction in step (e).
- the compounds having Formula I according to this invention are produced by subjecting the compounds having Formula II according to this invention to reduction such as, for example, chemical reduction or catalytic hydrogenation or, when the Base is one of uracil, thymidine, cytosine and guanine and wherein R is a member of said group of above-mentioned substituents, by first forming a 3',2-anhydro intermediate and then reacting the intermediate with an nucleophile to introduce a 3'-substituent.
- reduction such as, for example, chemical reduction or catalytic hydrogenation or, when the Base is one of uracil, thymidine, cytosine and guanine and wherein R is a member of said group of above-mentioned substituents
- the compounds having Formula II according to this invention are produced by the steps of:
- SCHEMES II and III below illustrate typical, representative processes to produce compounds having Formulas I and II, respectively, according to this invention.
- the processes so illustrated were used in the actual examples which follow and may be used with alternative and equivalent reactants including starting materials, intermediates and reagents as will be apparent to those skilled in the art to which this invention pertains.
- the starting material is a 2'-deoxy-2'-fluoroarabino-nucleoside.
- the above-mentioned starting compound can be obtained according to the procedures disclosed in the above-mentioned Brundidge et al . U.S. Patent 4,625,020 or Lopez et al. EP Pat. App. Pub. 0,010,205. More particularly, the preparation of the starting material, 1-(2-deoxy-2-fluoro-2- D -arabinofuranosyl) 5-iodouracil (also known as 2′-deoxy-2′-fluoroarabino-5-iodo uridine) is described in Procedure 7 in the Brundidge et al . patent.
- the starting material useful to make the compounds according to this invention can be produced by reacting a 2-deoxy-2-fluoroarabinofuranosyl halide of the formula V wherein R' and R'', independently, are acyl, alkyl, aryl selected from conventional hydroxy group protecting groups, with a suitable base such as, for example, the preferred, activated-as-needed purine and pyrimidine bases having Formulas III and IV respectively, wherein R1, R2, R3, R4, R5, and R6 are as defined above. Exemplary suitable procedures are described in U.S. Pat. 4,625,020 and EP Pat. App. Pub. 0,010,205.
- the processes according to this invention are useful for the preparation of a variety of 2′-fluoro-2′, 3′-dideoxynucleosides and 2′-fluoro-2′3′-dideoxy-2′,3′-didehydronucleosides, especially pyrimidine and purine nucleosides, having antiviral, antimetabolic, and antineoplastic activity as well as activity against human immunodeficiency viruses.
- the anti-HIV data of representative compounds according to this invention are set forth in TABLE I.
- the compound numbers refer to the following actual examples illustrating preparation of the compounds according to this invention.
- TABLE I ANTI-HIV in vitro ACTIVITY OF SELECTED 2'-FLUORO_2′,3′-DIDEOXY-NUCLEOSIDES NUMBER ABBR. NAME M.P. deg. C ID50 (50% inhib.
- the assays were done in HTLV-1 transofrmed MT-2 cells infected with HIV virus. Inhibition of cytopathic effect CPE) was measured seven days after infection in comparison with control infected cells (Elaine Kinney-Thomas, (Bioch. Pharm., vol.36,pp 311-316, 1987).
- 2′,3′-Dideoxy-2′-fluoroarabino-5′-monomethoxytrityl-uridine (840mg; 1.67mM) was stirred in dry pyridine (5ml) with p-chlorophenyl phosphodichloridate (1.23g, 0.814ml; 5.00mM) and 1,2,4-triazole (693mg, l0.0mM) for 3 days.
- the mixture was partitioned between CH2Cl2 and H2O and the organic extract was dried (Na2SO4) and evaporated. This resulting material was dissolved in 1,4-dioxane (15ml) and stirred for 4 hrs with 27% aqueous ammonia (8ml).
- the residue was purified on a silica gel column (25%EtOAc/CH2CL2 - 50%EtOAc/CH2CL2).
- the main product crystallised from CH2CL2-Et2O to give 2′,3′-dideoxy-2′-fluoroarabino-5′-(monomethoxytrityl-thymidine (2.7g).
- This material was stirred for 3hrs (45-55°C) in 80% aqueous acetic acid (20ml). The volatiles were removed in vacuo and the residue was crystallized from CH2CL2-Et2O-Hexane to give pure title compound (430mg).
- the title compound was prepared from 2′,3′-dideoxy-2′,3′dehydro-2′-fluoro-5′-monomethoxytrityl-uridine in a manner analogous to 2′,3′-dideoxy-2′-fluoroarabino-5′-monomethoxytrityl-cytidine.
Abstract
Description
- This invention relates to 2′,3′-dideoxy-2′-fluoronucleosides and 2′,3′-dideoxy-2′,3-didehydro-2′-fluoronucleosides, their preparation, and their use in HIV infection.
- Marquez et al., Biochem. Pharmacol., 36 (17), 2719-2722 (1987) disclose two 2′-F-substituted dideoxynucleoside derivatives of dideoxyadenosine (ddA; compound (A)) which constitute acid stable, active anti-HIV agents. These two compounds are shown below and designated compound B [6-amino-(β′D-2′,3′-dideoxy-2′-fluororibofuranosyl)-9-H-purine; 2′-F-ddA] and compound C [6-amino-9-(β-D-2′,3′-dideoxy-2′-fluoroarabinofuranosyl)-H-purine; 2′-F-ara-ddA].
Compound B was obtained from 3′-deoxy-ara-A (compound D) in four steps which involved protection of the 5′-hydroxyl group with dimethoxytrityl chloride, activation of the 2′-hydroxyl group via formation of the corresponding triflate, inversion of configuration at the 2′-position by an SN₂ displacement using tetra-n-butylammonium fluoride, and removal of the dimethoxytrityl protective group using dichloracetic acid. - Compound C was prepared by condensing 6-chloropurine with 3-O-acetyl-5-O-benzyl-2-deoxy-2-fluoro-D-arabinofuranosyl bromide, separating the expected four isomers and characterizing the correct 6-chloro isomer, and subjecting the correct isomer to ammonolysis with concentrated methanolic ammonia to give Compound E, 6-amino-9-(β-D-2′deoxy-2′-fluoroarabinofuranosyl)-9H-purine (2′F-ara-dA; compound E). Selective protection of the 5'-hydroxyl function of Compound E with t-butyldimethylsilyl chloride gave a product that permitted the 2-step reduction of the 3'-hydroxy group. Treatment with phenyl chlorothionocarbonate, followed by reduction of the intermediate 3'-O-phenoxythiocarbonyl derivative with tri-n-butyl tin hydride, produced the desired 2',3'-dideoxynucleoside. Removal of the 5'-blocking group with tetra-n-butyl ammonium fluoride gave 2'-F-ara-ddA (compound C).
- The results of biological testing showed that Compound C having stereochemistry of fluorine at the 2'-position in the β ("up") configuration provided a compound about as active and potent as AZT or ddA against HIV. Compound B having fluoride at the 2'-position in the α ("down") configuration gave dramatically different activity, being protective against HIV to 13% of that protection seen with ddA and was more toxic than ddA.
- U.S. Serial No. 028817, corresponding to EP-A-285 884, discloses a process for producing 2',3'-dideoxynucleosides represented by the formula.
The process for producing two representative dideoxynucleoside according to U.S. Serial No. 028817, corresponding to EP-A-285 884, is outlined in Scheme I below.
Brundidge et al., U.s. Patent 4,625,020, discloses a process for producing 1-halo-2-deoxy-2-fluoroarabinofuranoside derivatives (Compound of Formula F), bearing protective ester groups, from 1,3,5-tri-O-acyl-ribofuranose. The 1-halo derivatives are intermediates in the synthesis of therapeutically active nucleosidic compounds (compound of Formula G).
Lopez et al., EP Patent App. Publication No. 0,010,205 discloses 5-substituted 1-(2′-deoxy-2′-substituted-beta-D-arabinofuranosyl)pyrimidine nucleosides wherein the 2′-substituent, X, is halogen, alkylsulfonyl or arylsulfonyl (compound of Formula H). - This invention comprises novel 2',3'-dideoxy-2'-fluoronucleosides and 2'-3'-dideoxy-2',3'--didehydro-2'-fluoronucleosides and processes for their preparation. The compounds exhibit therapeutically useful antiviral effects and are useful as anti-human immunodeficiency virus (anti-HIV) infection agents.
-
- (a) B is a member selected from the group of bases consisting of purine (except adenine), aza-purine, deaza-purine, pyrimidine, aza-pyrimidine, deaza-pyrimidine, and triazole ring bases; and
- (b) R is selected from hydrogen (H) and a member of the group of substituents consisting of azido (N₃), cyano (CN), cyanamido (NHCN), halo (F, Cl, Br), amino (NH₂), monoalkylamino (NHR'), dialkylamino (NR₂'), alkylthio (SR'), sulfoxide (S(O)R') and sulfonyl (S(O)₂R') groups wherein R' is selected from C₁-C₃ alkyl, phenyl and tolyl groups, provided that R is not hydrogen when B is selected from cytosine, uracil, thymine, guanine or inosine.
-
- (a) B is a member selected from the group of bases consisting of purine (except adenine), aza-purine, deaza-purine, pyrimidine, aza-pyrimidine, deaza-pyrimidine, and triazole ring bases; and
- (b) R is selected from hydrogen (H) and a member of the group of substituents consisting of azido (N₃), cyano (CN), cyanamido (NHCN), halo (F, Cl, Br), amino (NH₂), monoalkylamino (NHR'), dialkylamino (NR₂'), alkylthio (SR'), sulfoxide (S(O)R') and sulfonyl (S(O)₂R') groups wherein R' is selected from C₁-C₃ alkyl, phenyl and tolyl groups.
- In yet another aspect, this invention is a process for producing a compound according to Formula I comprising the steps of:
- (a) reacting a 2'-deoxy-2'fluoroarabino-nucleoside with a hydroxy-protecting group reagent to selectively protect the 4'-hydroxymethyl group;
- (b) subjecting the intermediate from step (a) to reductive deoxygenation to convert the 3′-hydroxy group in the intermediate from step (a) to a 3′-hydrogen group; and
- (c) deprotecting the 4′-hydroxymethyl group.
- In still another aspect, this invention is a process for producing a compound according to Formula II comprising the steps of:
- (a) reacting a 2′-deoxy-2′-fluoroarabino-nucleoside with a hydroxy-protecting group reagent to selectively protect the 4′-hydroxymethyl group;
- (b) subjecting the intermediate from step (a) to reaction conditions effective to convert the 3′-hydroxy group to 3′-O-leaving group substituent;
- (c) subjecting the intermediate from step (b) to elimination reaction conditions to form a double bond between the 2′- and 3′-positions of the 5-membered ring system; and
- (d) deprotecting the 4′-hydroxymethyl group.
- In yet another aspect, this invention is a process for producing a compound according to Formula I comprising the steps of:
- (a) reacting a 2′-deoxy-2′-fluoroarabino-nucleoside with a hydroxy-protecting group reagent to selectively protect the 4′-hydroxymethyl group;
- (b) subjecting the intermediate from step (a) to reaction conditions effective to convert the 3′-hydroxy group to 3′-O-leaving group substituent;
- (c) subjecting the intermediate from step (b) to elimination reaction conditions to form a double bond between the 2'- and 3'-positions of the 5-membered ring system;
- (d) deprotecting the 4'-hydroxymethyl group; and
- (e) subjecting the intermediate from step (d) to reducing conditions effective to reduce the double bond connecting the 2' and 3' carbon atoms of the 5-membered ring system.
- In still another aspect, this invention is a process for producing a compound according to Formula-I wherein B is derived from a member of the group of bases consisting of uracil, thymine, cytosine, and guanine and wherein R is a member of said group of above-mentioned substituents comprising the steps of:
- (a) subjecting 2'-deoxy-2'-fluoroarabinonucleoside having a hydroxy protecting group at the 5'-position and a 3'-O-leaving group to conditions effective to form a 3',2-anhydro bond; and
- (b) reacting the intermediate from step (a) with a nucleophile effective to disrupt the 3',2-anhydro bond and to introduce the 3'-substituent.
- In yet another aspect, this invention is a pharmaceutical composition comprising an antiviral effective amount of the compound according to one of Formulas I and II and a pharmaceutically acceptable carrier.
- In still another aspect, this invention is a method of treating an animal to eliminate or reduce the infection with the human immunodeficiency virus (HIV) by administering to said animal an anti-human immunodeficiency virus effective amount of a compound according to one of Formulas I and II.
- As is mentioned above, the base component B is derived from a member selected from the group of bases consisting of purine (except adenine), aza-purine, deaza-purine, pyrimidine, aza-pyrimidine, deaza-pyrimidine, and triazole ring bases. Preferably, the base is selected from purine and pyrimidine bases. More preferably, the base is a pyrimidine base including one of the group of uracil, thymine and cytosine.
- Suitable purine bases include those purine bases represented by the structural formula
wherein R¹ and R² may be the same or different and are selected from hydrogen, hydroxy, halo (F, Cl, Br), amino, monoalkylamino, dialkylamino, alkoxy and cyano groups wherein the alkyl moiety is selected from C₁-C₃ alkyl groups, provided that R² is not H and R¹ is not NH₂. - Suitable pyrimidine bases include those pyrimidine bases represented by the structural formula
wherein R³ is selected from hydroxy, amino and sulfhydryl groups; R ⁴ is hydrogen; R⁵ is selected from hydroxy and amino groups; and R⁶ is selected from hydrogen, C₁-C₃ alkyl, C₂-C₃ alkenyl, C₂-C₃ haloalkenyl having from 1 to 5 halo groups as defined herein, C₂-C₃ alkynyl, alkoxy wherein the alkyl moiety has 1-3 carbon atoms, cyano and halo (F, Cl, Br and I). - When derived from purine bases, representative of B are the following:
2-aminopurin-9-yl
2,6-diaminopurin-9-yl
2-amino-6-hydroxypurin-9-yl (guanin-9-yl)
6-hydroxypurin-9-yl
In addition to the above, the B component may be 2-halopurin-9-yl, 6-halopurin-9-yl, or 2,6-dihalopurin-9-yl, in which event the base component need not be activated, for example, completely silylated, in order to undergo the condensation or coupling reaction in step (e). When derived from pyrimidine bases, representative of B are the following:
2,4-dihydroxypyrimidin-1-yl
5-methyl-2,4-dihydroxypyrimidin-1-yl
5-ethyl-2,4-dihydroxypyrimidin-1-yl
2-hydroxy-4-aminopyrimidin-1-yl
5-vinyl-2,4-dihydroxypyrimidin-1-yl
5-halovinyl-2,4-dihydroxypyrimidin-1-yl
5-halomethyl-2,4-dihydroxypyrimidin-1-yl
5-haloethyl-2,4-dihydroxypyrimidin-1-yl
The above-mentioned 5-methyl and 5-ethyl substituents are representative of 5-alkyl substituents and the 5-vinyl substituent is representative of 5-alkenyl substituents. Examples of halo-groups on the 5-halovinyl (or 5-haloalkenyl) group include 1 to 4 F, Cl, and Br groups. - The compounds having Formula I according to this invention are produced by the steps of:
- (a) reacting a 2'-deoxy-2'fluoroarabino-nucleoside base with a hydroxy-protecting group reagent to selectively protect the 4'-hydroxymethyl group;
- (b) subjecting the intermediate from step (a) to reductive deoxygenation to convert the 3'-hydroxy group in the intermediate from step (a) to a 3'-hydrogen group; and
- (c) deprotecting the 4'-hydroxymethyl group.
- Alternatively, the compounds having Formula I according to this invention are produced by subjecting the compounds having Formula II according to this invention to reduction such as, for example, chemical reduction or catalytic hydrogenation or, when the Base is one of uracil, thymidine, cytosine and guanine and wherein R is a member of said group of above-mentioned substituents, by first forming a 3',2-anhydro intermediate and then reacting the intermediate with an nucleophile to introduce a 3'-substituent.
- The compounds having Formula II according to this invention are produced by the steps of:
- (a) reacting a 2'-deoxy-2'-fluoroarabino-nucleoside with a hydroxy-protecting group reagent to selectively protect the 4'-hydroxymethyl group;
- (b) subjecting the intermediate from step (a) to reaction conditions effective to convert the 3'-hydroxy group to 3'-O-leaving group substituent;
- (c) subjecting the intermediate from step (b) to elimination reaction conditions to form a double bond between the 2'- and 3'-positions of the 5-membered ring system; and
- (d) deprotecting the 4'-hydroxymethyl group.
- SCHEMES II and III below illustrate typical, representative processes to produce compounds having Formulas I and II, respectively, according to this invention. The processes so illustrated were used in the actual examples which follow and may be used with alternative and equivalent reactants including starting materials, intermediates and reagents as will be apparent to those skilled in the art to which this invention pertains. As shown, the starting material is a 2'-deoxy-2'-fluoroarabino-nucleoside.
- The above-mentioned starting compound can be obtained according to the procedures disclosed in the above-mentioned Brundidge et al. U.S. Patent 4,625,020 or Lopez et al. EP Pat. App. Pub. 0,010,205. More particularly, the preparation of the starting material, 1-(2-deoxy-2-fluoro-2-D-arabinofuranosyl) 5-iodouracil (also known as 2′-deoxy-2′-fluoroarabino-5-iodo uridine) is described in Procedure 7 in the Brundidge et al. patent. When this compound is used as the starting material, it may conveniently be subjected to conventional catalytic dehalogenation to give 2′-deoxy-2′-fluoroarabino-uridine. Generally, the starting material useful to make the compounds according to this invention can be produced by reacting a 2-deoxy-2-fluoroarabinofuranosyl halide of the formula V
wherein R' and R'', independently, are acyl, alkyl, aryl selected from conventional hydroxy group protecting groups, with a suitable base such as, for example, the preferred, activated-as-needed purine and pyrimidine bases having Formulas III and IV respectively,
wherein R¹, R², R³, R⁴, R⁵, and R⁶ are as defined above. Exemplary suitable procedures are described in U.S. Pat. 4,625,020 and EP Pat. App. Pub. 0,010,205. - SCHEMES II and III summarize typical, representative processes to produce the compounds according to this invention starting from 2'-deoxy-2'-fluoroarabinothymidine. The given materials and the amounts thereof, the various reaction conditions employed in the several steps, and the means to isolate, purify, and characterize the several intermediates and final products will be readily apparent to those skilled in the art to which this invention pertains with this disclosure, including the actual examples which follow, in hand.
- Thus, the processes according to this invention are useful for the preparation of a variety of 2′-fluoro-2′, 3′-dideoxynucleosides and 2′-fluoro-2′3′-dideoxy-2′,3′-didehydronucleosides, especially pyrimidine and purine nucleosides, having antiviral, antimetabolic, and antineoplastic activity as well as activity against human immunodeficiency viruses.
- The following examples illustrate but a few representative embodiments of the compounds and processes according to this invention and are set forth to teach those skilled in the pertinent art how to practice this invention and are not to be construed as limiting in scope. All parts and percentages are by weight and temperatures are in degrees Celsius unless otherwise specified.
- The anti-HIV data of representative compounds according to this invention are set forth in TABLE I. The compound numbers refer to the following actual examples illustrating preparation of the compounds according to this invention.
TABLE I ANTI-HIV in vitro ACTIVITY OF SELECTED 2'-FLUORO_2′,3′-DIDEOXY-NUCLEOSIDES NUMBER ABBR. NAME M.P. deg. C ID50 (50% inhib. conc.) microM 3 2′-FddU 159-162 not tested 5 2′-FddC 203-205 4 7 2′-Fddt 162-164 >100 11 2′-Fd4T 129-131 10-100 16 2′-Fd4C 15-48 17 2′-FAZT oil >100 - The assays were done in HTLV-1 transofrmed MT-2 cells infected with HIV virus. Inhibition of cytopathic effect CPE) was measured seven days after infection in comparison with control infected cells (Elaine Kinney-Thomas, (Bioch. Pharm., vol.36,pp 311-316, 1987).
- 2′-Deoxy-2′-fluoroarabino-uridine (8.9g; 36.15mM) dissolved in dry pyridine (120ml) was heated for 8hrs with monomethoxytrityl chloride (11.423; 37.00mM) at 60-80°C and the volatiles were removed under vacuum. The residue was purified by column chromnatography on silica gel (20%EtOAc in CH₂Cl₂ to 40%EtOAc in CH₂Cl₂ followed by 10%EtOH in EtOAc) to give the title compound as an oil (7.4g,39.5%). 3.7 g of the starting material (s.m.) was recovered from EtOH/EtOAc washings. Yield: 67.57% based on consumed s.m..
- 2′-Deoxy-2′-fluoroarabino-5′-monomethoxytrityl-uridine (7.2g 13.88mM) was stirred in dimethylformamide (DMF; 60ml) for 2.7 hrs at 80-90°C with 1,1-thiocarbonyldiimidazole (3.46g, 19.41mM). The volatiles were removed in vacuo, and the oily residue (11g) suspended in toluene and treated with azobisisobutyronitrile (AIBN, 200mg), polymethylhydrosiloxane (40ml) and bis-tributyltin oxide (40ml). This mixture was heated under reflux for 6hrs under argon and volatiles were removed in vacuo. The residue was treated with hexane (400ml) and for 40 min. stirred at dry ice temp. The resulting supernatant was decanted, diluted with 100ml of hexane and kept over dry ice overnight. The resulting supernatant was decanted and the combined residues were purified on a silica gel column (13%EtOAc in CH₂Cl₂ to 40%EtOAc in CH₂Cl₂). Yield 4.1g(58.7%). PMR(360MHz;CDCl₃): 9.23(bs,1,NH), 7.53(dd,1.6Hz, 8.2Hz, 1 , H-6), 7.45-7.21m,12,aromatic), 6.83(m,2,aromatic), 6.05(dd, 18.0HZ,3.2Hz,1, H-1′), 5.58(d, 8.13Hz, 1, H-5), 5.19(dm, 56.3Hz,1,H-2′), 4.32(m, 1, H-4′), 3.78(s, 3, OCH₃), 3.32(m,2,H-5′), 2.47 - 2,34(m, 1, H-3a′), 2.28 - 2.03(m, 1, H-3′).
- 2′,3′-Dideoxy-2′-fluoroarabino-5′-monomethoxytrityl-uridine (1.7g;3.38mM) was dissoved in 80% aqueous acetic acid (80ml) and stirred for 2.5hrs at 55-65°C. The volatiles were removed in vacuo and the residue was crystallized from MeOH-Et₂O-Hexane to give the pure product(500mg). Additional material 110mg was obtained from mother liquor through chromatography on a silica column(10%EtOH in EtOAc). Total yield :610mg(78.4%).M.p.159-162°C. For C₉H₁₁N₂O₄F Calc.: 47.0%C, 4.8%H, 12.2%N. Found: 46.6%C, 4.9%H, 12.0%N. PMR(360MHz, d6 DMSO) 7.74(bd,8.1Hz, 1, H-6), 5.97(dd, 16.8Hz, 3.3Hz, 1, H-1′), 5.62(dd, 8.1Hz, 1.6Hz, 1, H-5), 5.28(dm, 54.8Hz, 1, H-2′), 5.01(t, 5.8Hz, 1, OH), 4.095(m, 1, H-4′), 3.52(m, 2, H-5′), 2.54-2.38(m, 1, H-3a′), 2.2 - 1.98(m, 1, H-3b′).
- 2′,3′-Dideoxy-2′-fluoroarabino-5′-monomethoxytrityl-uridine (840mg; 1.67mM) was stirred in dry pyridine (5ml) with p-chlorophenyl phosphodichloridate (1.23g, 0.814ml; 5.00mM) and 1,2,4-triazole (693mg, l0.0mM) for 3 days. The mixture was partitioned between CH₂Cl₂ and H₂O and the organic extract was dried (Na₂SO₄) and evaporated. This resulting material was dissolved in 1,4-dioxane (15ml) and stirred for 4 hrs with 27% aqueous ammonia (8ml). The volatiles were removed in vacuo and remaining oil was purified on a silica gel column (3%EtOH/EtOAc - 10%EtOH/EtOAc) to give the title product (590mg,70.4%). PMR(200MHz, CDCl₃): 7.56(dd, 7.6Hz, 3.0Hz, 1, H-6), 7.50 - 7,20(m, 12, aromatic), 6.85(m, 2, aromatic), 6.08(dd, 18.2Hz, 3.6Hz, 1, H-1′), 5.61(d, 7.8Hz, 1, H-5), 5.21(dm, 54.4Hz, 1, H-2′), 4.35(m, 1, H-4′), 3.28(m, 2, H-5′), 2.62-2.06(m, 2, H-3′).
- 2′,3′-Dideoxy-2′-fluoroarabino-5′-monomethoxytrityl-cytidine 420mg; 0.837mM) was stirred for 3 hrs. in 80% aqueous acetic acid (15ml) at 60°C. The volatiles were removed in vacuo and the residue filtered through a short silica gel column (5%EtOH/EtOAc - 30%EtOH/EtOAc) to give the title cpd. The product was recrystallized several times from EtOH. Yield: 89mg(46.4%). M.p. 203-205°C. For C₉H₁₂N₃O₃F Calc.:47.2%C; 5.3%H;Found: 46.8%C; 5.3%H. PMR(360MHz,d6 DMSO):
7.67(dd, 6.7Hz, 1.5Hz, 1, H-6), 7.19(bd, 2, NH2), 5.93(dd, 18.7Hz, 3.5Hz, 1, H-1′), 5.71(d, 6.7Hz, 1, H-5), 5.21(dm,51.5, 1, H-2′), 4.94(t, 5.8Hz, 1, OH), 4.08(m, 1, H-4′), 3.51(m, 2, H-5′), 2.6 - 2.4(m, 1, H-3a′), 2.12 - 2.198(m, 1, H-3b′). - 2′-Deoxy-2′-fluoroarabino-5-methyluridine(10.4g; 40mM) dissolved in anhydrous pyridine (150ml) was heated at 65-75deg. C for 6hrs. with monomethoxytrityl chloride (13.9g,45.0mM). The reaction mixture was poured into ice-water (1.51) with vigorous stirring. The precipitate was filtered off, but turned oily upon standing (21.1g;99.0% crude). PMR(200MHz, CDCl₃): 8.83(bs, 1, NH), 7.5-7.18(m, 13, aromatic and H-6), 6.84(d, 2, aromatic), 6.27(dd, 18.8Hz, 3.2Hz, 1, H-1′), 5.04(dm, 51.6Hz, 1, H-2′), 4.46(dd, 20.2Hz, 4.0Hz, 1, H-3′), 4.01(q, 4.6Hz, 1, H-4′), 3.80(s, 3, OCH₃), 3.51 - 3.37(m, 2, H-5′), 1.75(bs, 3, CH=CCH₃).
- Crude 2′-deoxy-2′-fluoroarabino-5′-monomethoxytrityl-thymidine (7.0g,13.14mM) was heated at 80deg. C for 2.5hrs with 1,1-thiocarbonyldiimidazole (2.67g, 15.0mM) and the volatiles were removed in vacuo. The residue was heated to reflux in toluene (380ml) with AIBN (120mg), bis-tri-n-butyltin oxide (29ml) and polymethylhydrosiloxane (29ml). The volatiles were removed in vacuo and the residue was triturated with hexane (250ml), cooled in dry ice, and the supernatant was discarded. The residue was purified on a silica gel column (25%EtOAc/CH₂CL₂ - 50%EtOAc/CH₂CL₂). The main product crystallised from CH₂CL₂-Et₂O to give 2′,3′-dideoxy-2′-fluoroarabino-5′-(monomethoxytrityl-thymidine (2.7g). This material was stirred for 3hrs (45-55°C) in 80% aqueous acetic acid (20ml). The volatiles were removed in vacuo and the residue was crystallized from CH₂CL₂-Et₂O-Hexane to give pure title compound (430mg). This product was recrystallized with the material obtained from the silica gel column purification of the mother liquor (10%EtOH/EtOAc) to give analytically pure material (810mg, 25.2% overall). M.p. 162 - 164°C. For C₁₀H₁₃N₂O₄F Calc: 49.2%C; 5.4%H; 11.5%N. Found: 49.2%C; 5.4%H; 11.3%N. PMR(360MHz, d6 DMSO): 7.61(bs, 1, H-6), 5.95(dd, 16.6Hz, 3.8Hz, 1, H-1′), 5.26(dm, 54.9Hz, 1, H-2′), 4.07(m, 1, H-4′), 3.62 - 3.48(m, 2, H-5′), 2.53 - 2.37(m, 1, H-3a′, 2.13 - 1.98(m, 1, H-3b′), 1.77(bs, 3, CH=CCH₃).
- 2′-deoxy-2′-fluoroarabino-5′-monomethoxytrityl-thymidine (10g; 18.78mM in dry pyridine (65ml) was treated dropwise at 0°C with methanesulfonyl chloride (6ml; 61.4mM) and kept at 0°C overnight. The volatiles were removed in vacuo and the residue was purified on silica gel column (25%EtOAc/CH₂Cl₂ to 45%EtOAc/CH₂Cl₂) to an oily product (7.0g,61%). PMR(200MHz, CDCl₃): 8.40(bs, 1, NH), 7.55-7.20(m, 13, aromatic and H-6), 6.87(bd, 2, aromatic), 6.25(dd, 19.6Hz, 3.6Hz, 1, H-1′), 5.38(dd, 17.6Hz, 3.4Hz, 1, H-3′), 5.29(dd, 48Hz, 3.6Hz,1, H-2′), 4.17(m, 1, H-4′), 3.81(s, 3, OCH₃), 3.51(m, 2, H-5′), 3.06(s, 3, OSO₂CH₃), 1.74(bs, 3, CH=CCH₃)
- 2′-Deoxy-2′-fluoroarabino-3′-methanesulfonyl-5′-monomethoxytrityl-thymidine (2.7g; 4.42mM) was dissolved in EtOH (200ml) and heated under relux for 2 hrs with 1N NaOH (4.6ml). The volatiles were removed in vacuo, and the product was washed into a filtering funnel with cold water. Yield: 1.7g(74.6%). PMR(200MHz, CDCl₃):7.5-7.2(m, 12,aromatic), 6.92(s, 1, H-6), 6.80(bd, 2, aromatic), 5.37(dt, 52.0Hz, 3.4Hz, 1, H-2′), 5.36(m, 1, H-1, H-1′) 5.03(t, 3.2Hz,1, H-3′), 4.33(m, 1, H-4′), 3.77(s, 3, OCH₃), 3.36(bd, 2, H-5′), 1.94(bs, 3, CH=CCH₃).
- 2′,3′-Dideoxy-3′,2-anhydro-2′-fluoroarabino-5′-monomethoxytrityl-thymidine (412mg; 0.8mM) and tBuOK (199.8mg,1.78mM) were suspended in dry DMSO(7ml) and stirred for 0.5hr at room temperature under argon. The reaction mixture was poured into ice-water and acidified to pH 5.0 with 80%AcOH. The precipitate was filtered off (200mg), but turned oily upon standing. Additional material was obtained from EtOAc extraction of the water layer. Crude product was purified on a silica gel column (45%EtOAc/Hexane - 50%EtOAc/Hexane) to give pure product (190mg, 46.1%). PMR(360MHz, CDCl₃): 8.22(bs, 1, NH), 7.47(s, 1, H-6), 7.4 - 7.20(m, 12, aromatic), 6.92(dd, 4.5Hz, 1.4Hz, 1, H-3′), 6.80(m, 2, aromatic), 5.69(d, 1.3Hz,1,H-1′), 4.93(m, 1, H-4′), 3.77(s, 3, OCH₃), 3.35 (AB of ABX, 2, H-5′), 2.03(bs, 1, CH=CCH₃).
- 2′,3′-Dideoxy-2′,3′-didehydro-2′-fluoro-5′-monomethoxytrityl-thymidine (300mg;0.583mM) was stirred for 1.5hrs at 60°C in 80% acetic acid (5ml) and the volatiles were removed in vacuo. The residue was purified on a silica gel column (3%EtOH in EtOAc-CH₂Cl₂ 1:1 to 5%EtOH in the same) to give the title nucleoside (40mg; 28.3%). The product was recrystallized from CH₂Cl₂-Hexane. M.p. 129-131°C (decomposition). PMR(200MHz d6 DMSO): 7.89(bs, 1, H-6), 6.75(m, 1, H-3′), 5.99(s, 1, H-1′), 5.16(t, 5.4Hz, 1, OH), 4.80(m, 1, H-4′), 3.61(m, 2, 2 ,H-5′), 1.76(bs, 3, CH=CCH₃).
- The title compound was obtained from 2′-deoxy-2′-fluoroarabino-5′-monomethoxytrityl-uridine in a mesylation analogous to the mesylation of 2′-deoxy-2′-fluoroarabino-5′-monomethoxytrityl-thymidine. Yield: >99% crude. PMR(200MHz, CDCl₃): 8.52(bs, 1, NH), 7.54 - 7.20(m, 13, aromatic and H-6), 6.84 - 6.89(m, 2, aromatic), 6.23 (dd, 18.4Hz, 3.4Hz, 1, H-1′), 5.58(dd, 8.2Hz, 2.0Hz, 1, H-5),5.36(dm, 20.6Hz, 1, H-3′), 5.30(dm, 50.6Hz, 1, H-2′), 4.196(m, 1, H-4′), 3.81(s, 3, OCH₃), 3.515(bd, 2, H-5′), 3.07( s, 3, OSO₂CH₃).
- 2′-deoxy-2′-fluoroarabino-3′-methanesulfonyl-5′-monomethoxytrityl-uridine (20g;33.5mM) in EtOH (400ml) was treated with 1N NaOH(35ml) and heated under reflux for 4hrs. The mixture was cooled down to 5°C and the pH adjusted to 7.5 with 80% AcOH. The precipitate was filtered off, washed with MeOH-water and dried. Yield 14.0g (83.5%). PMR(360MHz, d6 DMSO): 7.76 (d, 7.45Hz, 1, H-6), 7.37 - 7.19(m, 12, aromatic), 6.88(d, 2, aromatic), 6.03(bd, 4.8Hz, 1, H-1′), 5.91(dt, 50.0Hz, 3.6Hz, 1, H-2′), 5.89(d, 7.3Hz, 1, H-5),5.43(t, 2.7Hz, 1, OH), 4.60(m, 1, H-4′), 3.72(s, 3, OCH₃), 3.13(m, 2, H-5′).
- 2′,3′-dideoxy-3′,2-anhydro-2′-fluoroarabino-5′-monomethoxytrityl-uridine (4.2g; 8.39mM) and potassium t-butoxide (2.1g; 18.75mM) were stirred at r.t. in dry DMSO (120 ml) for 60min. This mixture was poured into ice-water (600ml) and extracted with EtOAc amd dried. Yield: 4.0g (95.2%), sufficiently pure for subsequent transformations.
PMR(360MHz, CDCl₃): 8.41(bs, 1, NH), 7.92(d, 8.1Hz, 1, H-6), 7.35-7.19(m, 12, aromatic), 6.88(m, 1, H-3′), 6.83(d, 2, aromatic), 5.62(s, 1, H-1′), 5.04(d, 8.14Hz, 1, H-5), 4.89(m, 1, H-4′), 3.43,(m, 2, H-5′). - The title compound was prepared from 2′,3′-dideoxy-2′,3′dehydro-2′-fluoro-5′-monomethoxytrityl-uridine in a manner analogous to 2′,3′-dideoxy-2′-fluoroarabino-5′-monomethoxytrityl-cytidine. Yield: 18.8% PMR(200MHz, d6 DMSO): 7.71(d, 7.4Hz, 1, H-6), 7.38 - 7.19(m, 12, aromatic), 6.88(m, 3, aromatic and H-3′), 6.07(m, 1, H-1′), 5.37(d, 7.4Hz, 1, H-5), 4.90(m, 1, H-4′), 3.75(s, 3, OCH3), 3.60(m, 2, H-5′).
- 2′3′-Dideoxy-2′,3′-dehydro-2′-fluoro-5′-monomethoxytrityl-cytidine (750mg, 3.30mM) was stirred in 80% AcOH (5ml) for 5hrs at r.t. The volatiles were removed in vacuo, and the product was purified on silica column to give 240mg (70.4%) of the title compound. For C₉H₁₀FN₃O₃ Calc.: 47,6%C, 4.4%H, 18.5%N. Found: 47.4%C 4.4%H, 18.5%N.
PMR(360MHz, d6 DMSO): 7.85(d, 7.4Hz, 1, H-6), 7.32(bd, 2, NH2), 6.84(bs, 1, H-3′), 5.93(s, 1, H-1′), 5.76(d, 7.4Hz, 1, H-5), 5.05(t, 5.3Hz, 1, OH), 4.75(m, 1, H-4′), 3.55(m, 3, H-5′). - 2′,3′-Dideoxy-3′,2-anhydro-2′-fluoroarabino-5′-monomethoxytrityl-thymidine (850mg; 1.65mM) in DMF(25ml) was stirred for 62hrs at 105°C with lithium azide(980mg, 20mM).
A few crystals of potassium carbonate were added and the mixture was partitioned between water and ethyl acetate. Unreacted s.m. (140mg) crystallized out upon trituration with ether-methylene chloride. The mother liquor (700mg) was dissolved in 80% AcOH (5ml) and stirred for 6hrs at 35deg. C. Crude product was purified on a silica gel column (50%EtOAc in CH₂Cl₂) to give the title cpd (150mg, 31.9% overall). For C₁₀H₁₂N₅O₄F Calc.:42.1%C, 4.2%H. Found: 42.3%C, 4.1%H. PMR(360MHz, DMSOd6): 11.46(bs, 1, NH), 7.60(s, 1, H-6), 6.14(dd, 10.9Hz, 5.4Hz, 1, H-1′), 5.37(dt, 54.0Hz, 5.4Hz, 1, H-2′), 5.34(bs, 1, OH), 4.51(ddd, 22.4Hz, 7.5Hz, 5.3Hz, 1, H-3′), 3.82(m, 1, H-4′), 3.68(m, 2, H-5′), 1.77(bs, 3, CH=CCH₃). - 2′,3′-Dideoxy-2′,3′-didehydro-2′-fluoro-5′-monomethoxytrityl-uridine (450mg, 0.9mM) was hydrogenated over 10%Pd/C (85mg) in ethanol (60ml) solution for 2hrs. Filtration and evaporation of the solvent in vacuo yielded the crude product, which was subsequently purified on a silica gel column (15%EtOAc in CH₂Cl₂ to 25% EtOAc in CH₂Cl₂). Yield: 300mg (66.4%) MS(EI): M⁺ 502. This compound is identical to the one obtained through the deoxygenation route, described before.
Claims (10)
- A compound having the formula(a) B is derived from a member selected from the group of bases consisting of purine (except adenine), aza-purine, deaza-purine, pyrimidine, aza-pyrimidine, deaza-pyrimidine, and triazole ring bases; and(b) R is selected from hydrogen (H) and a member of the group of substituents consisting of azido (N₃), cyano (CN), cyanamido (NHCN) halo (F, Cl, Br), amino (NH₂), monoalkylamino (NHR'), dialkylamino (NR₂'), alkylthio (SR'), sulfoxide (S(O)R') and sulfonyl (S(O)₂R') groups wherein R' is selected from C₁-C₃ alkyl, phenyl, and tolyl groups, provided that R is not hydrogen when B is selected from cytosine, uracil, thymine, guanine or inosine.
- A compound having the formula(a) B is derived from a member selected from the group of bases consisting of purine (except adenine), aza-purine, deaza-purine, pyrimidine, aza-pyrimidine, deaza-pyrimidine, and triazole ring bases; and(b) R is selected from hydrogen (H) and a member of the group of substituents consisting of azido (N₃), cyano (CN), cyanamido (NHCN) halo (F, Cl, Br), amino (NH₂), monoalkylamino (NHR'), dialkylamino (NR₂'), alkylthio (SR'), sulfoxide (S(O)R') and sulfonyl (S(O)₂R') groups wherein R' is selected from C₁-C₃ alkyl, phenyl, and tolyl groups.
- A compound according to Claims 1 or 2 wherein B is selected from purine and pyrimidine bases.
- A compound according to anyone of claims 1 to 3 wherein B is a purine base group represented by the structural formula
- A compound according to anyone of claims 1 to 3 wherein B is a pyrimidine base group represented by the structural formula
- A process for producing a compound of formula I as defined in claims 1,3,4, or 5 comprising the steps of:(a) reacting a 2'-deoxy-2'-fluoroarabinonucleoside with a hydroxy-protecting group reagent to selectively protect the 4'-hydroxymethyl group;(b) subjecting the intermediate from step (a) to reductive deoxygenation to convert the 3'-hydroxy group in the intermediate from step (a) to a 3'-hydrogen group; and(c) deprotecting the 4'-hydroxymethyl group,or(a) reacting a 2'-deoxy-2'fluoroarabinonucleoside with a hydroxy-protecting group reagent to selectively protect the 4'-hydroxymethyl group;(b) subjecting the intermediate from step (a) to reaction conditions effective to convert the 3'-hydroxy group to 3'-O-leaving group substituent;(c) subjecting the intermediate from step (b) to elimination reaction conditions to form a double bond between the 2'- and 3'-positions of the 5-membered ring system;(d) deprotecting the 4'-hydroxymethyl group; and(e) subjecting the intermediate from step (d) to reducing conditions effective to reduce the double bond connecting the 2' and 3' carbon atoms of the 5-membered ring system.
- A process for producing a compound according to Formula I wherein B is derived from a member of the group of bases consisting of uracil, thymine, cytosine, and guanine and wherein R is a member of said group of substituents comprising the steps of:(a) subjecting 2'-deoxy-2'-fluoroarabinonucleoside having hydroxy protecting group at the 5'-position and a 3'-O-leaving group to conditions effective to form a 3',2-anhydro bond; and(b) reacting the intermediate from step (a) with an nucleophile effecting to disrupt the 3',2-anhydro bond and to introduce the 3'-substituent.
- A process for producing a compound of formula II as defined in Claims 2 to 5 comprising the steps of:(a) reacting a 2'-deoxy-2'-fluoroarabinonucleoside with a hydroxy-protecting group reagent to selectively protect the 4'-hydroxymethyl group;(b) subjecting the intermediate from step (a) to reaction conditions effective to convert the 3'-hydroxy group to 3'-O-leaving group substituent;(c) subjecting the intermediate from step (b) to elimination reaction conditions to form a double bond between the 2'- and 3'- positions of the 5-membered ring system; and(d) deprotecting the 4'-hydroxymethyl group.
- A process for preparing a pharmaceutical composition which comprises incorporating an antiviral effective amount of at least one compound according to anyone of Claims 1 to 5 into a pharmaceutical acceptable carrier.
- The use of at least one compound according to anyone of Claims 1 to 5 for preparing a pharmaceutical composition for eliminating or reducing an infection with the human immunodeficiency virus.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT88118870T ATE100461T1 (en) | 1987-11-12 | 1988-11-11 | 2',3'-DIDEOXY-2'-FLUORUCLEOSIDES. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/120,051 US4908440A (en) | 1987-11-12 | 1987-11-12 | 2',3'-dideoxy-2'-fluoroarabinopyrimidine nucleosides |
US120051 | 1987-11-12 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0316017A2 EP0316017A2 (en) | 1989-05-17 |
EP0316017A3 EP0316017A3 (en) | 1990-05-30 |
EP0316017B1 true EP0316017B1 (en) | 1994-01-19 |
Family
ID=22387985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP88118870A Expired - Lifetime EP0316017B1 (en) | 1987-11-12 | 1988-11-11 | 2',3'-Dideoxy-2'-fluoronucleosides |
Country Status (22)
Country | Link |
---|---|
US (4) | US4908440A (en) |
EP (1) | EP0316017B1 (en) |
JP (4) | JPH01153698A (en) |
KR (1) | KR920004459B1 (en) |
AT (1) | ATE100461T1 (en) |
AU (1) | AU615960B2 (en) |
CA (1) | CA1340961C (en) |
CZ (3) | CZ278394B6 (en) |
DD (1) | DD275874A5 (en) |
DE (1) | DE3887273T2 (en) |
DK (1) | DK173971B1 (en) |
ES (1) | ES2061609T3 (en) |
FI (1) | FI90244C (en) |
HU (1) | HU199499B (en) |
IE (1) | IE62227B1 (en) |
IL (1) | IL88330A (en) |
NO (1) | NO169492C (en) |
NZ (1) | NZ226845A (en) |
PT (1) | PT88994B (en) |
SK (2) | SK278017B6 (en) |
YU (1) | YU47121B (en) |
ZA (1) | ZA888313B (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5495010A (en) * | 1987-04-17 | 1996-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | Acid stable purine dideoxynucleosides |
US5459256A (en) * | 1987-04-17 | 1995-10-17 | The Government Of The United States Of America As Represented By The Department Of Health And Human Services | Lipophilic, aminohydrolase-activated prodrugs |
US5631370A (en) * | 1988-01-20 | 1997-05-20 | Regents Of The University Of Minnesota | Optically-active isomers of dideoxycarbocyclic nucleosides |
US5175292A (en) * | 1988-01-20 | 1992-12-29 | Regents Of The University Of Minnesota | Intermediates for the preparation of dideoxycarbocyclic nucleosides |
US5644043A (en) * | 1988-02-16 | 1997-07-01 | Eli Lilly And Company | 2',3'-dideoxy-2',2'-difluoronucleosides and intermediates |
US5198539A (en) * | 1988-08-19 | 1993-03-30 | Burroughs Wellcome Co. | 5'-esters of 2',3'-dideoxy-3'-fluoro-5-ethynyluridine |
GR1000618B (en) * | 1989-03-17 | 1992-08-31 | Oncogen | Method for the hiv suppression by using nucleosidic associations derivatives |
FI95384C (en) * | 1989-04-06 | 1996-01-25 | Squibb Bristol Myers Co | Process for the preparation of 3'-deoxy-3'-substituted methyl nucleosides and intermediates used in the process |
SE464168B (en) * | 1989-07-19 | 1991-03-18 | Bo Fredrik Oeberg | ANTIVIRAL COMPOSITION CONSISTING OF A 3'-FLUORO-2 ', 3'-DIDEOXYNUCLEOSIDE COMPOUND AND AND 2', 3'-DIDEOXYNUCLEOSIDE COMPOUND (EXAMPLE AZT) |
ATE311399T1 (en) * | 1989-09-15 | 2005-12-15 | Southern Res Inst | 2'-DEOXY-4'-THIORIBONUCLEOSIDE AS ANTIVIRAL AND ANTICANCER AGENTS |
US5817799A (en) * | 1990-07-23 | 1998-10-06 | The United States Of America As Represented By The Department Of Health And Human Services | 2'-Fluorofuranosyl derivatives and methods for preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides |
US5420115A (en) * | 1990-09-10 | 1995-05-30 | Burroughs Wellcome Co. | Method for the treatment of protoza infections with 21 -deoxy-21 -fluoropurine nucleosides |
AU1254892A (en) * | 1990-12-18 | 1992-07-22 | Sloan-Kettering Institute For Cancer Research | Novel synthesis of 2'-"up" fluorinated 2''-deoxy-arabinofuranosylpurines |
US5712477A (en) * | 1996-05-14 | 1998-01-27 | Allen-Bradley Company, Inc. | System to provide alignment and troubleshooting aid photoelectric sensors through alternating numeric display |
CN101240001B (en) * | 1998-02-25 | 2013-10-16 | 埃莫里大学 | 2'-fluoro nucleotide |
DE69933860T2 (en) * | 1998-02-25 | 2007-05-31 | Emory University | 2'-FLUORONUKLEOSIDE |
CA2426187C (en) | 2000-10-18 | 2011-08-16 | Pharmasset Limited | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation |
US6949522B2 (en) | 2001-06-22 | 2005-09-27 | Pharmasset, Inc. | β-2′- or 3′-halonucleosides |
US20050131224A1 (en) * | 2003-12-15 | 2005-06-16 | Cti Pet Systems, Inc. | Method for preparing radiolabeled thymidine |
US7160537B2 (en) * | 2003-12-15 | 2007-01-09 | Siemens Medical Solutions Usa, Inc. | Method for preparing radiolabeled thymidine having low chromophoric byproducts |
US8895531B2 (en) | 2006-03-23 | 2014-11-25 | Rfs Pharma Llc | 2′-fluoronucleoside phosphonates as antiviral agents |
US20070243798A1 (en) * | 2006-04-18 | 2007-10-18 | 3M Innovative Properties Company | Embossed structured abrasive article and method of making and using the same |
KR20160076373A (en) | 2014-12-22 | 2016-06-30 | 김기범 | Rope assembly for install of shell for farming |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE292023C (en) * | ||||
US4211773A (en) * | 1978-10-02 | 1980-07-08 | Sloan Kettering Institute For Cancer Research | 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides |
CA1340645C (en) * | 1987-04-17 | 1999-07-13 | Victor E. Marquez | Acid stable dideoxynucleosides active against the cytopathic effects of human immunodeficiency virus |
GB8712115D0 (en) * | 1987-05-22 | 1987-06-24 | Hoffmann La Roche | Pyrimidine derivatives |
JPH01100190A (en) * | 1987-10-12 | 1989-04-18 | Asahi Glass Co Ltd | Nucleosides |
NZ226672A (en) * | 1987-10-30 | 1991-07-26 | Hoffmann La Roche | 6-amino-9-(2,3-dideoxy-2-fluoro-b-d-threopentofuranosyl)-9h-purine derivatives and pharmaceutical compositions |
-
1987
- 1987-11-12 US US07/120,051 patent/US4908440A/en not_active Expired - Lifetime
-
1988
- 1988-11-04 NZ NZ226845A patent/NZ226845A/en unknown
- 1988-11-04 YU YU204888A patent/YU47121B/en unknown
- 1988-11-07 ZA ZA888313A patent/ZA888313B/en unknown
- 1988-11-09 IL IL8833088A patent/IL88330A/en not_active IP Right Cessation
- 1988-11-09 FI FI885153A patent/FI90244C/en not_active IP Right Cessation
- 1988-11-09 NO NO884995A patent/NO169492C/en unknown
- 1988-11-11 JP JP63284077A patent/JPH01153698A/en active Pending
- 1988-11-11 IE IE340688A patent/IE62227B1/en not_active IP Right Cessation
- 1988-11-11 EP EP88118870A patent/EP0316017B1/en not_active Expired - Lifetime
- 1988-11-11 PT PT88994A patent/PT88994B/en not_active IP Right Cessation
- 1988-11-11 SK SK5452-90A patent/SK278017B6/en unknown
- 1988-11-11 CZ CS905451A patent/CZ278394B6/en not_active IP Right Cessation
- 1988-11-11 DK DK198806316A patent/DK173971B1/en not_active IP Right Cessation
- 1988-11-11 AU AU25042/88A patent/AU615960B2/en not_active Ceased
- 1988-11-11 CZ CS905452A patent/CZ278395B6/en not_active IP Right Cessation
- 1988-11-11 CZ CS887431A patent/CZ278366B6/en not_active IP Right Cessation
- 1988-11-11 ES ES88118870T patent/ES2061609T3/en not_active Expired - Lifetime
- 1988-11-11 DD DD88321728A patent/DD275874A5/en unknown
- 1988-11-11 KR KR1019880014854A patent/KR920004459B1/en not_active IP Right Cessation
- 1988-11-11 SK SK7431-88A patent/SK277919B6/en unknown
- 1988-11-11 AT AT88118870T patent/ATE100461T1/en not_active IP Right Cessation
- 1988-11-11 DE DE3887273T patent/DE3887273T2/en not_active Expired - Fee Related
- 1988-11-11 HU HU885779A patent/HU199499B/en not_active IP Right Cessation
- 1988-11-14 CA CA000583061A patent/CA1340961C/en not_active Expired - Fee Related
-
1989
- 1989-07-11 US US07/378,331 patent/US4973677A/en not_active Expired - Lifetime
-
1990
- 1990-09-13 US US07/581,941 patent/US5126506A/en not_active Expired - Lifetime
-
1992
- 1992-03-26 US US07/857,850 patent/US5218106A/en not_active Expired - Lifetime
-
1993
- 1993-05-24 JP JP5155977A patent/JP2699049B2/en not_active Expired - Fee Related
- 1993-05-24 JP JP5155978A patent/JP2699050B2/en not_active Expired - Fee Related
-
1997
- 1997-01-22 JP JP9009099A patent/JP2811561B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0316017B1 (en) | 2',3'-Dideoxy-2'-fluoronucleosides | |
US6090932A (en) | Method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement | |
JP4012579B2 (en) | Nucleosides and oligonucleotides having 2'-ether groups | |
JP3530218B2 (en) | Novel process for producing N4 -acyl-5'-deoxy-5-fluorocytidine derivatives | |
US5607922A (en) | 1,5-anhydrohexitol nucleoside analogues | |
US4837311A (en) | Anti-retroviral compounds | |
WO1991016333A1 (en) | 2',3'-dideoxy-4'-thioribonucleosides as antiviral agents | |
EP0595839A4 (en) | ||
CA2442979C (en) | Process for the preparation of 2'-halo-.beta.-l-arabinofuranosyl nucleosides | |
JPH06228186A (en) | 2'-deoxy-@(3754/24)2's)-alkylpyrimidine nucleoside derivative | |
US5336764A (en) | 2'-fluorofuranosyl derivatives and novel method of preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides | |
Chu et al. | Nucleosides. 107. Synthesis of 5-(. beta.-D-arabinofuranosyl) isocytosine and related C-nucleosides | |
KR920004982B1 (en) | 2',3'-dideoxy-2'-fluoro-nucleostides | |
USRE33887E (en) | Anti-retroviral compounds | |
JP3059479B2 (en) | Novel antiviral agent and method for producing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BRISTOL-MYERS SQUIBB COMPANY |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19901108 |
|
17Q | First examination report despatched |
Effective date: 19920221 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE ES FR GB GR IT LI LU NL SE |
|
REF | Corresponds to: |
Ref document number: 100461 Country of ref document: AT Date of ref document: 19940215 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 3887273 Country of ref document: DE Date of ref document: 19940303 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: FG4A Free format text: 3010510 |
|
ITF | It: translation for a ep patent filed |
Owner name: MODIANO & ASSOCIATI S.R.L. |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2061609 Country of ref document: ES Kind code of ref document: T3 |
|
26N | No opposition filed | ||
EAL | Se: european patent in force in sweden |
Ref document number: 88118870.0 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20031105 Year of fee payment: 16 Ref country code: NL Payment date: 20031105 Year of fee payment: 16 Ref country code: GB Payment date: 20031105 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20031110 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20031112 Year of fee payment: 16 Ref country code: AT Payment date: 20031112 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20031118 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20031120 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20031127 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20031209 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20040121 Year of fee payment: 16 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041111 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041111 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041111 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041112 Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041112 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041130 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041130 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20041130 |
|
BERE | Be: lapsed |
Owner name: *BRISTOL-MYERS SQUIBB CY Effective date: 20041130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050601 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050601 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050602 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20041111 |
|
EUG | Se: european patent has lapsed | ||
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20050729 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20050601 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20051111 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20041112 |
|
BERE | Be: lapsed |
Owner name: *BRISTOL-MYERS SQUIBB CY Effective date: 20041130 |